HTR2A and Parkinsonism: This is in line with clinical data on the effect of trazodone, suggesting that increasing 5-HT2A antagonisme improves Parkinson’s symptoms (Werneck et al., 2009) and has been demonstrated in an earlier version of the model before (Spiros et al., 2013).